Compare XBIO & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XBIO | CWD |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 5.3M |
| IPO Year | 2011 | 2022 |
| Metric | XBIO | CWD |
|---|---|---|
| Price | $1.93 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.2K | ★ 330.0K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.52 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,976,411.00 | ★ $20,097,000.00 |
| Revenue This Year | $2.37 | N/A |
| Revenue Next Year | N/A | $19.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.04 | N/A |
| 52 Week Low | $1.85 | $0.40 |
| 52 Week High | $4.94 | $3.35 |
| Indicator | XBIO | CWD |
|---|---|---|
| Relative Strength Index (RSI) | 32.29 | 34.42 |
| Support Level | N/A | N/A |
| Resistance Level | $2.53 | $0.60 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 11.03 | 9.38 |
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
CaliberCos Inc is an asset management firm investing across real and digital assets. It sponsors and manages private real estate investment funds and maintains a digital asset treasury approach focused on blockchain infrastructure assets. The company's activities are supported by transaction and advisory services, including development and construction management, acquisition and disposition services, brokerage, and fund formation services. The company operates through one reportable segment. It generates the majority of its revenue in the form of asset management fee revenues and performance allocations.